The present invention relates to a recombinant vector carrying cellulose-binding domain 3 and a method for separating a target protein using the recombinant vector. The protein isolating method of the present invention can easily separate a fusion protein containing a target protein by using the recombinant vector to bind a transformed plant body to cellulose and can effectively isolate the target protein from a cellulose-binding domain by treating the fusion protein with enterokinase, thus being expected to find industrial applications in various fields.

Disclosed herein are methods for high-throughput screening of a functional antibody fragment for an immunoconjugate that targets a protein antigen. The method combines a phage-displayed synthetic antibody library and high-throughput cytotoxicity screening of non-covalently assembled immunotoxins or cytotoxic drug to identify highly functional synthetic antibody fragments for delivering toxin payloads.

The invention provides a sensitive cell-based assay, in which stably expressed mutant Huntingtin (mHTT) fragments serve as biosensors to detect mHTT species present in biosamples or can be used to identify novel compounds for use as therapeutics for the treatment of HD.

New insecticidal nucleotides, peptides, polypeptides, and proteins, and their expression in plants; methods of producing new peptides; new processes and production techniques; new formulations; new organisms; and a process which increases the insecticidal peptide production yield from yeast expression systems. The present invention is also directed to insecticidal peptides we call cysteine rich insecticidal peptides (CRIPS), and mixtures and/or compositions thereof with pore-forming insecticidal proteins (PFIPs). The present invention also describes mixtures and compositions of CRIPs with Bacillus thuringiensis (Bt), and the genes and/or proteins therefrom, in various formulations and combinations, of both genes and peptides, useful for the control of insects.

Provided herein are NK-92 cells expressing at least one CAR and at least one Fc receptor. Also provided are methods of treatment of a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient NK-92-Fc-CAR.

The invention relates to protein-based T-cell receptor knockdown, and its use in T-cell therapies.

The present invention provides a cell which comprises; (i) a chimeric antigen receptor (CAR) which comprises an antigen binding domain and an intracellular signalling domain; and (isi) a membrane-tethered signal-dampening component (SDC) comprising a signai-dampening domain (SDD).

A hook fusion protein, which includes a hook domain and at least one cytoplasmic carboxyl endoplasmic reticulum (ER) retention signal and/or at least one cytoplasmic amino terminal endoplasmic reticulum (ER) retention signal; wherein the hook fusion protein is a soluble protein that localizes in the cytoplasm. Also, a nucleic acid system for intracellular targeting control including a nucleic acid encoding a target fusion protein including a hook fusion protein, and a nucleic acid encoding a target fusion protein including a hook-binding domain; wherein the target fusion protein is a membrane protein; and wherein the hook fusion protein localizes in the ER when bound to the target fusion protein. Additionally, a vector system, viral particle system, host cell and kit include these nucleic acids. Further, the vector system, viral particle system, host cell or kit for use as a medicament, in particular for immunotherapy.

The present invention relates to an engineered immune cell which comprises: (i) a target binding polypeptide comprising a target-binding domain and a first protein interaction domain, and (ii) a localising polypeptide comprising a second protein interaction domain, which binds to the first protein binding domain, and an intracellular retention signal. When the target binding polypeptide binds its target protein and also the localising polypeptide, expression of the target protein at the cell surface is reduced or eliminated because the target protein is retained in an intracellular compartment.

Provided are recombinant polypeptides that comprise a protein of interest, a protein localization tag, and a protease cleavage site disposed between the protein of interest and the protein localization tag. In certain embodiments, the recombinant polypeptides further comprise a protease, where the protease cleavage site is a cleavage site for the protease. Also provided are nucleic acids that encode the recombinant polypeptides, cells that comprise such nucleic acids, and compositions (e.g., pharmaceutical compositions) that comprise such cells. Methods of regulating cellular localization of a protein of interest, and methods of administering a regulatable cell-based therapy to an individual in need thereof, are also provided.